Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

In-Bore Versus Fusion MRI–Targeted Biopsy of PI-RADS Category 4 and 5 Lesions: A Retrospective Comparative Analysis Using Propensity Score Weighting

“…European Society of Medical Oncology suggesting that all patients with suspected prostate cancer should undergo MRI before biopsy also reflect the shift towards an MRI-targeted approach to prostate cancer diagnosis [10,11].…”

BRCA Mutations in Prostate Cancer: Prognostic and Predictive Implications

“…The US National Comprehensive Cancer Network (NCCN) guidelines recommend genetic testing (somatic and/or germline) for patients with high, very-risk, regional, and metastatic PCa or with a significant family history for cancer [ 44 ]. The recently published European Society for Medical Oncology (ESMO) guidelines recommend germline screening for all patients with mPCa and to consider genetic testing in patients with localized PCa and a family history suggestive for hereditary cancer predisposition [ 45 ]. Multidisciplinary discussion and integration with genetic services are fundamental to decide when and whether a genetic test should be performed and to select the appropriate therapeutic and diagnostic strategies.…”

Systematic Literature Review of the Epidemiology of Advanced Prostate Cancer and Associated Homologous Recombination Repair Gene Alterations

“…Reference source not found.). [5][6][7][8] The National Comprehensive Cancer Network (NCCN) guidelines recommend tumor testing for HRRm in men with advanced PC; germline testing for patients with a positive family history or Ashkenazi Jewish ancestry or men with high-risk, extreme high-risk, regional, or metastatic disease; and germline testing for patients who are HRRm+ on tumor testing. 5 In 2020, for mCRPC, the Food and Drug Administration in the United States (US) has approved olaparib for HRRm (except for PPP2R2A) post-abiraterone acetate and enzalutamide treatment and rucaparib for BRCA1/2 mutation post-androgen receptor-directed therapy and taxane chemotherapy.…”